Immunome, Inc. Financing Cash Flow
Immunome, Inc. (IMNM) reported Financing Cash Flow of $923.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- Immunome, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.06M.
- Immunome, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$135.00K, a 100.08% decline year-over-year.
- Immunome, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $432.80M, a 2054.82% increase year-over-year.
- Immunome, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $45.39M, a 14781.64% increase year-over-year.
- Immunome, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $640.36M, a 166.23% increase from fiscal 2024.
- Immunome, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $240.53M, a 106.63% increase from fiscal 2023.
- Immunome, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $116.41M, a 363675.00% increase from fiscal 2022.
- Immunome, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $32.00K, a 99.88% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $923.00K 10-Q · filed 2026-08-11 | $433.72M derived: sum of 3 quarters · filed 2026-08-11 | $479.11M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$135.00K 10-Q · filed 2026-05-12 | $432.66M derived: sum of 2 quarters · filed 2026-05-12 | $478.05M derived: sum of 3 quarters · filed 2026-05-12 | $477.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $432.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $478.18M derived: sum of 2 quarters · filed 2026-03-03 | $478.13M derived: sum of 3 quarters · filed 2026-08-11 | $640.36M 10-K · filed 2026-03-03 |
| 2025-09-30 | $45.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $45.33M derived: sum of 2 quarters · filed 2026-08-11 | $207.56M 10-Q · filed 2025-11-06 | $227.65M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $162.17M 10-Q · filed 2026-08-11 | $182.26M derived: sum of 3 quarters · filed 2026-08-11 | $182.56M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $162.23M 10-Q · filed 2026-05-12 | $182.31M derived: sum of 2 quarters · filed 2026-05-12 | $182.62M derived: sum of 3 quarters · filed 2026-05-12 | $183.31M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $20.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $20.39M derived: sum of 2 quarters · filed 2026-03-03 | $21.08M derived: sum of 3 quarters · filed 2026-03-03 | $240.53M 10-K · filed 2026-03-03 |
| 2024-09-30 | $305.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $999.00K derived: sum of 2 quarters · filed 2025-11-06 | $220.44M 10-Q · filed 2025-11-06 | $275.94M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $694.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $220.14M 10-Q · filed 2025-08-06 | $275.64M derived: sum of 3 quarters · filed 2025-08-06 | $336.51M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $219.44M 10-Q · filed 2025-05-12 | $274.94M derived: sum of 2 quarters · filed 2025-05-12 | $335.82M derived: sum of 3 quarters · filed 2025-05-12 | $335.82M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $55.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $116.37M derived: sum of 2 quarters · filed 2025-03-19 | $116.37M derived: sum of 3 quarters · filed 2025-03-19 | $116.41M 10-K · filed 2025-03-19 |
| 2023-09-30 | $60.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $60.88M derived: sum of 2 quarters · filed 2024-11-13 | $60.91M 10-Q · filed 2024-11-13 | $60.91M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $34.00K 10-Q · filed 2024-08-12 | $34.00K derived: sum of 3 quarters · filed 2024-08-12 | $34.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $34.00K 10-Q · filed 2024-05-14 | $34.00K derived: sum of 2 quarters · filed 2024-05-14 | $34.00K derived: sum of 3 quarters · filed 2024-05-14 | $34.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 derived: sum of 3 quarters · filed 2024-03-28 | $32.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $32.00K 10-Q · filed 2023-11-09 | -$163.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $32.00K 10-Q · filed 2023-08-09 | -$163.00K derived: sum of 3 quarters · filed 2023-08-09 | $422.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $32.00K 10-Q · filed 2023-05-05 | -$163.00K derived: sum of 2 quarters · filed 2023-05-05 | $422.00K derived: sum of 3 quarters · filed 2023-05-05 | $27.72M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | -$195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $390.00K derived: sum of 2 quarters · filed 2023-03-16 | $27.69M derived: sum of 3 quarters · filed 2023-03-16 | $27.77M 10-K · filed 2023-03-16 |
| 2021-09-30 | $585.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $27.89M derived: sum of 2 quarters · filed 2022-11-14 | $27.96M 10-Q · filed 2022-11-14 | $67.09M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $27.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $27.38M 10-Q · filed 2022-08-05 | $66.51M derived: sum of 3 quarters · filed 2022-08-05 | $66.11M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $76.00K 10-Q · filed 2022-05-12 | $39.21M derived: sum of 2 quarters · filed 2022-05-12 | $38.81M derived: sum of 3 quarters · filed 2022-05-12 | $49.17M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $39.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $38.74M derived: sum of 2 quarters · filed 2022-03-28 | $49.10M derived: sum of 3 quarters · filed 2022-03-28 | $49.94M 10-K · filed 2022-03-28 |
| 2020-09-30 | -$393.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $9.97M derived: sum of 2 quarters · filed 2021-11-15 | $10.81M 10-Q · filed 2021-11-15 | $15.24M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $10.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $11.21M 10-Q · filed 2021-08-16 | $15.63M derived: sum of 3 quarters · filed 2021-08-16 | |
| 2020-03-31 | $844.00K 10-Q · filed 2021-05-12 | $5.27M derived: sum of 2 quarters · filed 2021-05-12 | ||
| 2019-12-31 | $4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $10.77M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $6.34M 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |